WS #16952
Corporate earnings are providing mixed signals amidst the broader market turmoil. Pfizer reported a revenue miss for Q3 2026 ($16.6B), while Arcutis also missed estimates, adding to the negative sentiment in the healthcare sector. Conversely, Iron Mountain raised its full-year revenue outlook and increased its quarterly dividend by 15%, signaling resilience in the data storage and infrastructure business. These mixed results highlight the divergence between cyclical tech and defensive infrastructure plays.
Corporate Earnings & Guidance
Corporate earnings are providing mixed signals amidst the broader market turmoil. Pfizer reported a revenue miss for Q3 2026 ($16.6B), while Arcutis also missed estimates, adding to the negative sentiment in the healthcare sector. Conversely, Iron Mountain raised its full-year revenue outlook and increased its quarterly dividend by 15%, signaling resilience in the data storage and infrastructure business. These mixed results highlight the divergence between cyclical tech and defensive infrastructure plays.